iFeed Weekly: the algorithmic evidence shift — regulators are reviewing with AI; sponsors must file with AI.

The FDA has weaponised its own data architecture. Reviewers are no longer manually navigating fragmented submission systems — HALO consolidates the agency's historical submission layers into a unified intelligence stack, and Elsa 4.0 sits on top as the AI review surface. Cross-referencing across decades of filings, deficiency letters, label histories, and inspection records is now near-instantaneous from the reviewer's chair.

What breaks now: organisations operating through spreadsheet-driven compliance and disconnected QMS environments will hit major review friction. AI-assisted reviewers identify broken traceability chains, conflicting prior statements, and inconsistencies across the company's own submission history within seconds — gaps that previously took months of inspection-cycle exposure to surface.

As of 28 April 2026, the amended UK Clinical Trial Regulations are fully active. ICH E6(R3) is no longer a target document or a guidance horizon — it is the enforceable operating expectation against which MHRA inspectors are running their checks. The principles-based architecture (proportionate quality management, fit-for-purpose oversight, sponsor accountability for vendor performance) is now what the inspection looks for.

What breaks now: inspectors are evaluating whether systems actively prevent protocol deviations, data-integrity gaps, and vendor failures — not whether SOPs covering those topics exist on a shelf. RBQM evidence, real-time monitoring outputs, and demonstrable vendor-oversight artefacts are now the auditable layer. "We have a procedure" is no longer a defence; the evidence of operation is.

The FDA is restructuring evidence architecture. Single pivotal trial + confirmatory evidence is shifting from special-case pathway to default expectation across an expanding set of programmes. Confirmatory evidence is being interpreted broadly: real-world evidence (RWE), adaptive-design read-outs, external control arms, and Bayesian borrowing from prior trials are all in scope where the data quality supports it.

What breaks now: sponsors who are still defaulting to duplicate Phase III as the evidence-generation strategy are structurally overinvesting in redundant infrastructure. Capital that historically flowed into a second confirmatory trial is now better deployed into RWE pipelines, evidence-synthesis platforms, and the analytical infrastructure to defend a single pivotal + confirmatory package against agency review.

FDA and EMA issued a joint statement establishing unified Good AI Practice principles across the medicine lifecycle — from discovery and non-clinical through trial conduct, manufacturing, pharmacovigilance, and post-market surveillance. AI has formally shifted from experimental tooling into regulated scientific infrastructure, with paired transatlantic expectations on context-of-use, model transparency, performance monitoring, and lifecycle governance.

What breaks now: black-box vendors without explainability artefacts, model cards, performance-drift monitoring, or documented validation against context-of-use will become non-viable inside regulated environments. Procurement teams now need to ask AI vendors for evidence of governance, not just demonstrations of capability.

FDA has escalated enforcement around incomplete analytical data traceability and audit-trail integrity. Recent Warning Letters have collapsed inspection focus onto raw evidence: instrument audit logs, sequence integrity, electronic-signature records, and the path from raw acquisition file to final reportable result. The static PDF deliverable is no longer the surface that matters — the auditable lineage behind it is.

What breaks now: QA teams accustomed to reviewing final analytical reports must now validate the full data lineage. Legacy lab systems without complete audit-trail capture, instruments with shared-account histories, and any workflow that reconstructs results outside the validated pipeline are now inspection-vulnerable. "The report is correct" no longer answers "can you show me how it was generated?"

CDSCO has replaced prior-approval requirements with accelerated notification routes for selected categories of BA/BE studies. India is explicitly positioning regulatory speed as competitive infrastructure for the generic and biosimilar ecosystem — reducing pre-study agency friction in exchange for stronger retrospective inspection and stronger sponsor accountability.

What breaks now: operational liability now sits directly on the sponsor and CRO governance systems. The pre-approval gate that historically caught protocol and QA gaps is gone for the affected categories; the inspection that arrives after the study runs is now the controlling layer. CROs running BA/BE studies in India under the new routes need their own governance maturity to substitute for the agency's removed checkpoint.

Regulatory submissions are shifting from discrete static-PDF deliverables into continuously reconciled intelligence pipelines. EDC, EHR, RWE, manufacturing, pharmacovigilance, and bioanalytical nodes are converging into a living data fabric that feeds both the submission and the agency's own review intelligence. The document is no longer the deliverable — the reconciled, queryable dataset is.

What breaks now: teams whose operating model is "assemble the document at the end" cannot keep pace. The work shifts from manual document assembly into managing data pipelines, validating algorithms, and engineering the governance layer that sits between source systems and submission outputs. Job descriptions, vendor stacks, and QA capability all move with it.

Global ICH M10 (Bioanalytical Method Validation, Step 4 finalised 2022) adoption is accelerating — FDA, EMA, MHRA, PMDA, Health Canada are operative; CDSCO India and ANVISA Brazil are at varying stages of formal transposition. The harmonised text is moving faster than the SOP layer beneath it: site procedures and method-validation reports still cite the legacy EMA Guideline on Bioanalytical Method Validation (2011) as the validation reference, even where M10 is the operative guideline for the submission.

What breaks now: an inspector at a site running multi-region submissions encounters a citation chain that points to a guideline the agency itself has retired. Supersession needs to be reflected in SOPs, validation templates, and audit-trail documentation. The harmonised arc is real progress; the local catch-up is the audit-readiness gap.

The EU AI Act (Regulation (EU) 2024/1689) entered into force on 1 August 2024. High-risk obligations under Annex III — which catch a substantial portion of pharma and medtech AI deployments — become applicable on 2 August 2026. The compliance window for regulated healthcare AI is rapidly narrowing; the conformity-assessment infrastructure (Notified Bodies, harmonised standards, technical-documentation expectations) is being assembled in parallel, and the runway for restructuring an AI stack is now measured in months.

What breaks now: non-compliant AI vendors risk exclusion from regulated EU environments. Sponsors and providers must audit their AI inventories against Annex III categories, classify each deployment, and restructure documentation, monitoring, and conformity-assessment routes before enforcement. AI inventories that are still being built rather than already classified are on the wrong side of the timeline.